Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDC Launches Two Variants of COVID-19 Drug Favipiravir in India at ₹55 Per Tablet
Details : PiFLU (favipiravir), is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase, which is indicated for the treatment of COVID-19 infection.
Product Name : PiFlu
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable